PTCT241220P36000
- 1.40
- 0.000.00%
PTC Therapeutics Newsroom
Raymond James, Cantor Bullish on UniQure Following FDA Update
Cantor Fitzgerald Says 'Aggressively' Buy UniQure, PTC Therapeutics
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
PTC Therapeutics: Hold Rating Amid Strategic Collaboration With Novartis and Clinical Uncertainties
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $32
PTC Therapeutics(PTCT.US) Officer Sells US$5.02 Million in Common Stock
PTC Therapeutics(PTCT.US) Officer Sells US$3.73 Million in Common Stock
Citigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $32
Express News | Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $42
PTC Therapeutics Price Target Raised to $71 From $47 at UBS
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $56
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $41 to $68
UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating
Express News | Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $70
Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $56
PTC Therapeutics Analyst Ratings
Cautious Outlook on PTC Therapeutics Amid Regulatory Uncertainties and Clinical Data Gaps
PTC Therapeutics Price Target Raised to $56 From $45 at Barclays